NeuBase Therapeutics, Inc. Annual Return On Equity in % from 2012 to 2022

Taxonomy & unit
ratio: %
Description
Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
Summary
NeuBase Therapeutics, Inc. quarterly/annual Return On Equity history and growth rate from 2012 to 2022.
  • NeuBase Therapeutics, Inc. Return On Equity for the quarter ending September 30, 2023 was -104 %, a 6.35% decline year-over-year.
  • NeuBase Therapeutics, Inc. annual Return On Equity for 2022 was -97.3 %, a 59.7% decline from 2021.
  • NeuBase Therapeutics, Inc. annual Return On Equity for 2021 was -60.9 %, a 32.5% increase from 2020.
  • NeuBase Therapeutics, Inc. annual Return On Equity for 2020 was -90.3 %, a 94.7% increase from 2019.
Return On Equity, Annual (%)
Return On Equity, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date
2022 -97.3 -36.4 -59.7% Oct 1, 2021 Sep 30, 2022
2021 -60.9 +29.4 +32.5% Oct 1, 2020 Sep 30, 2021
2020 -90.3 +1.63K +94.7% Oct 1, 2019 Sep 30, 2020
2019 -1.72K -1.62K -1666% Oct 1, 2018 Sep 30, 2019
2018 -97.2 +2.77 +2.77% Oct 1, 2017 Sep 30, 2018
2017 -100 -19.7 -24.6% Oct 1, 2016 Sep 30, 2017
2016 -80.3 -42 -110% Oct 1, 2015 Sep 30, 2016
2015 -38.3 +19.5 +33.8% Oct 1, 2014 Sep 30, 2015
2014 -57.8 +96.1 +62.5% Oct 1, 2013 Sep 30, 2014
2013 -154 -531 -141% Oct 1, 2012 Sep 30, 2013
2012 377 Oct 1, 2011 Sep 30, 2012
* An asterisk sign (*) next to the value indicates that the value is likely invalid.